

# Jeanny B Aragon-Ching

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5608796/jeanny-b-aragon-ching-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

2,809  
citations

26  
h-index

51  
g-index

153  
ext. papers

3,413  
ext. citations

6.2  
avg. IF

5.42  
L-index

#	Paper	IF	Citations
137	Advances with androgen deprivation therapy for prostate cancer.. <i>Expert Opinion on Pharmacotherapy</i> , <b>2022</b> , 1-19	4	2
136	Contemporary treatment and survival differences in patients with urothelial versus nonurothelial bladder and upper tract carcinomas: Analyses from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 463-463	2.2	0
135	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 487-487	2.2	4
134	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. <i>Nature Communications</i> , <b>2022</b> , 13, 1878	17.4	1
133	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. <i>Oncoscience</i> , <b>2021</b> , 8, 40-45	0.8	0
132	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4520-4520	2.2	1
131	Comparative analyses of survival differences in patients with urothelial versus non-urothelial upper tract carcinomas: Results from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16582-e16582	2.2	
130	Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5079-5079	2.2	0
129	Protein kinase inhibitors for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 1889-1899	4	2
128	Pembrolizumab use in bladder cancer: a tale of two trials. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 577-578	5.5	2
127	The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. <i>Asian Journal of Andrology</i> , <b>2021</b> , 23, 1-2	2.8	6
126	The emerging role of checkpoint inhibitors for rare genitourinary cancers. <i>Nature Reviews Urology</i> , <b>2021</b> , 18, 133-134	5.5	
125	Plasmacytoid Variant of Urothelial Carcinoma: Poor Prognostic Variant with High Expression of CDH1 Mutation. <i>Uro</i> , <b>2021</b> , 1, 23-29		1
124	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	2
123	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2021</b> , 15, 11795549211044963	1.8	3
122	Role of immunotherapy in bladder cancer. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 26, 100296	2	11
121	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 483-490	3.5	0

120	Characterization of Brain Metastases in Urothelial Cancers. <i>Clinical Genitourinary Cancer</i> , <b>2020</b> , 18, e679-683	3.9	0
119	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , <b>2020</b> , 12, 819-831	3.8	7
118	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, LBA1-LBA1	2.2	44
117	Darolutamide for treatment of castration-resistant prostate cancer. <i>Drugs of Today</i> , <b>2020</b> , 56, 185-193	2.5	2
116	Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2020</b> , 22, 76-78	2.8	2
115	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , <b>2020</b> , 21, 105-120	21.7	35
114	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , <b>2020</b> , 47, 457-467	2.9	2
113	Maintenance avelumab for metastatic urothelial cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 1095-1096	4.6	4
112	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1218-1230	59.2	294
111	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2019</b> , 39, 262-275	7.1	3
110	The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2019</b> , 13, 1179554919833927	1.8	17
109	Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 657-666	4.6	9
108	Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 436-442	3.3	5
107	Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2296-2297	2.2	2
106	Molecular profiling of aggressive variant urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 378-378	2.2	3
105	Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 402-402	2.2	2
104	Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2019</b> , 21, 107-108	2.8	1
103	Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: A pathoepidemiological analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 403-403	2.2	1

102	Non-urothelial bladder cancer: Genomic alterations and patient outcomes.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 399-399	2.2	1
101	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. <i>Kidney Cancer</i> , <b>2019</b> , 3, 81-91	0.6	1
100	Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , <b>2019</b> , 20, 6-7	4.6	4
99	Epithelioid Angiosarcoma of the Bladder: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, e1091-e1095	3.3	3
98	Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 425-425	2.2	3
97	Role of chemotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2018</b> , 20, 221-229	2.8	43
96	Molecular characterization of brain metastases in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 509-509	2.2	
95	Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2018</b> , 38, 307-318	7.1	21
94	Vitamin D in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2018</b> , 20, 244-252	2.8	32
93	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1341-1367	2.2	75
92	Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 462-464	2.8	10
91	Mucinous Signet-Ring Urachal Carcinoma of the Bladder: Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, e889-e891	3.3	0
90	Targeted therapies in the treatment of urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 465-472	2.8	13
89	Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Cancer Management and Research</i> , <b>2017</b> , 9, 299-306	3.6	2
88	Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 914	2.2	2
87	Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> ,	3.3	18
86	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 390, 2266-2277	4.0	121
85	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 330-336	7.1	3

84	Retrospective review of clear cell and non-clear cell renal carcinomas: Characteristics and course in the pre-TKI (tyrosine kinase inhibitor) and post-TKI era.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16052-e16052	2.2	1
83	Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 99-99	2.2	1
82	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 330-336	7.1	5
81	Survival outcomes for de novo versus primary progressive metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 258-258	2.2	
80	Survival outcomes and patterns of utilization of cytoreductive nephrectomy in the tyrosine kinase inhibitors (TKI)-era in metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC): Analyses from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16068-e16068	2.2	
79	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10, 57-66	1.8	25
78	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. <i>Future Oncology</i> , <b>2016</b> , 12, 2049-58	3.6	5
77	The promising role of nivolumab in renal cell cancers. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 123-4	4.6	6
76	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1500-9	2.2	65
75	A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5065-5065	2.2	1
74	The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2016</b> , 16, 1166-71	2.2	2
73	The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. <i>Asian Journal of Andrology</i> , <b>2016</b> , 18, 592-3	2.8	2
72	Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 74-74	2.2	
71	Incidence and characterization of pure non-urothelial bladder and upper tract cancers: A 10-year review.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 414-414	2.2	
70	Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHARTED. <i>Asian Journal of Andrology</i> , <b>2016</b> , 18, 444-5	2.8	
69	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10, 11-9	1.8	22
68	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , <b>2016</b> , 10s1, CMO.Ss30751	1.8	2
67	A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). <i>Annals of Oncology</i> , <b>2016</b> , 27, vi292	10.3	10

66	Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , <b>2015</b> , 13, e341-5	3.3	9
65	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2015</b> , 11, 2395-403	3.6	1
64	2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , <b>2015</b> , 51, S476	7.5	3
63	Radium-223 for the treatment of castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , <b>2015</b> , 8, 1103-9	4.4	8
62	A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1059-73	5.9	7
61	Characterization of differences between prostate cancer (PCa) patients presenting as de novo versus primary progressive metastatic disease.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 285-285	2.2	
60	Pilot study assessing distressors affecting patients with cancer using the distress screening tool.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 68-68	2.2	
59	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2014</b> , 64, 225-49	220.7	258
58	Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , <b>2014</b> , 10, 651-64	2.9	6
57	Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2014</b> , 16, 803-4	2.8	1
56	Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 1299-300	4.6	5
55	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4169-70	2.2	4
54	Advances in systemic therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , <b>2014</b> , 10, 2213-26	3.6	4
53	The evolution of prostate cancer therapy: targeting the androgen receptor. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 295	5.3	26
52	Circulating Tumor Cells <b>2014</b> , 19, 229-233		
51	Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, 229-37	3.3	20
50	Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature. <i>Clinical Genitourinary Cancer</i> , <b>2013</b> , 11, e24-6	3.3	6
49	Primary diffuse large B-cell lymphoma of the ureter in a patient with HIV: a case report and review of literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 324-6	2	6

48	Metastatic castration-resistant prostate cancer: critical review of enzalutamide. <i>Clinical Medicine Insights: Oncology</i> , <b>2013</b> , 7, 235-45	1.8	15
47	Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. <i>Prostate Cancer</i> , <b>2013</b> , 2013, 210686	1.9	30
46	The changing landscape in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2013</b> , 5, 25-40	5.4	38
45	Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 179-179	2.2	1
44	Hematuria in sickle cell trait: the importance of ruling out occult cancer. <i>Annals of Hematology</i> , <b>2012</b> , 91, 137-8	3	1
43	Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , <b>2012</b> , 14, 805-6	2.8	5
42	Treatment of adult soft tissue sarcoma: old concepts, new insights, and potential for drug discovery. <i>Cancer Investigation</i> , <b>2012</b> , 30, 300-8	2.1	9
41	Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 144-7	2	7
40	Unravelling the role of denosumab in prostate cancer. <i>Lancet, The</i> , <b>2011</b> , 377, 785-6	40	15
39	Positron emission tomography findings in clinical mimics of lymphoma. <i>Annals of the New York Academy of Sciences</i> , <b>2011</b> , 1228, 19-28	6.5	6
38	Reimbursement policy and androgen-deprivation therapy for prostate cancer. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 579-80; author reply 580	59.2	4
37	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , <b>2011</b> , 10, 743-53	5.2	15
36	Implications for chemoprevention of prostate cancer with intake of cruciferous vegetables. <i>Asian Journal of Andrology</i> , <b>2011</b> , 13, 357-8	2.8	1
35	Angiogenesis inhibition in prostate cancer: current uses and future promises. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 361836	4.5	24
34	New Pharmacotherapies in the Treatment of Advanced Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , <b>2010</b> , 4, CMU.S5075	0	
33	Active surveillance for prostate cancer: has the time finally come?. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e265-6; author reply e267	2.2	5
32	About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?. <i>Annals of Oncology</i> , <b>2010</b> , 21, 183-4	10.3	3
31	The use of 5-alpha reductase inhibitors for the prevention of prostate cancer. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 11-2	4.6	1



30	Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2010</b> , 10, 593-600	2.2	1
29	Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2010</b> , 7, 31-35		6
28	Mucosa-associated lymphoma tissue of the dura presenting as meningioma. <i>Southern Medical Journal</i> , <b>2010</b> , 103, 950-2	0.6	10
27	Investigational Angiogenesis Inhibitors <b>2010</b> , 225-232		
26	Angiogenesis inhibitors in prostate cancer therapy. <i>Discovery Medicine</i> , <b>2010</b> , 10, 521-30	2.5	13
25	Phase I study of oral lenalidomide in patients with refractory metastatic cancer. <i>Journal of Clinical Pharmacology</i> , <b>2009</b> , 49, 650-60	2.9	45
24	Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e261; author reply e262	2.2	1
23	Further analysis of the survival benefit of clodronate. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2221-2	4.6	3
22	Cytotoxic compounds in the treatment of castration-resistant prostate cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2009</b> , 9, 1040-5	2.2	1
21	. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7749	12.9	
20	Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1411-6	12.9	118
19	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , <b>2009</b> , 103, 1636-40	5.6	102
18	Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. <i>Cancer Investigation</i> , <b>2009</b> , 27, 221-6	2.1	102
17	Anti-angiogenesis approach to genitourinary cancer treatment. <i>Update on Cancer Therapeutics</i> , <b>2009</b> , 3, 182-188		16
16	A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. <i>Journal of Urology</i> , <b>2009</b> , 181, 1104-13; discussion 1113	2.5	33
15	VEGF inhibitors and prostate cancer therapy. <i>Current Molecular Pharmacology</i> , <b>2009</b> , 2, 161-8	3.7	44
14	Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. <i>Journal of Urology</i> , <b>2008</b> , 180, 1432-7; discussion 1437	2.5	30
13	ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4543-9	12.9	117



12	A phase II clinical trial of sorafenib in androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 209-14	12.9	151
11	Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 4200-5	12.9	177
10	Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. <i>Acta Oncologica</i> , <b>2008</b> , 47, 1600-1	3.2	18
9	Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association?. <i>Oncologist</i> , <b>2008</b> , 13, 1314; author reply 1315	5.7	4
8	The role of angiogenesis inhibitors in prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2008</b> , 14, 20-5	2.2	27
7	The Clinical Utility of Bevacizumab <b>2008</b> , 375-385		2
6	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. <i>Frontiers in Bioscience - Landmark</i> , <b>2007</b> , 12, 4957-71	2.8	118
5	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. <i>BJU International</i> , <b>2007</b> , 100, 1245-8	5.6	
4	CNS metastasis: an old problem in a new guise. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 1644-7	12.9	79
3	Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 1959 <sup>2</sup> -1959 <sup>4</sup>		
2	Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?. <i>Cancer Therapy</i> , <b>2007</b> , 5A, 151-160		12
1	Thalidomide analogues as anticancer drugs. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , <b>2007</b> , 2, 167-74.6		55